Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval
Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining th...
Gespeichert in:
Veröffentlicht in: | General hospital psychiatry 2023-03, Vol.81, p.15-21 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 21 |
---|---|
container_issue | |
container_start_page | 15 |
container_title | General hospital psychiatry |
container_volume | 81 |
creator | Okayasu, Hiroaki Shinozaki, Takahiro Takano, Yumiko Sugawara, Norio Fujii, Kumiko Yasui-Furukori, Norio Ozeki, Yuji Shimoda, Kazutaka |
description | Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining the association between DC and the corrected QT interval (QTc) in schizophrenia patients.
We measured the DC and QTc of 138 schizophrenia patients. We then compared the DC of 86 age- and sex-matched healthy controls with that of 86 schizophrenia patients. We investigated the correlation of DC of approximately 138 schizophrenia patients with prescribed doses of antipsychotics using linear regression analysis. We compared the DC of schizophrenia patients with and without prolonged QT intervals.
We found DC significantly differed between schizophrenia patients on antipsychotic medication and healthy controls. Additionally, DC was negatively correlated with antipsychotic use, especially chlorpromazine, zotepine, olanzapine and clozapine, in a dose-dependent manner. There was no significant association between DC and the QTc.
Assessing DC could facilitate monitoring and identification of increased risk of cardiac mortality in patients with schizophrenia that take antipsychotics. Assessing both DC and the QTc may enhance the accuracy of predicting sudden cardiac death.
•The association of DC with antipsychotic use was examined in 138 persons with schizophrenia.•DC was significantly lower in schizophrenia using medication than in normal controls.•Antipsychotic use had a negative dose-dependent relationship with DC.•Using of chlorpromazine, zotepine, olanzapine, and clozapine was correlated with DC.•No association was observed between DC and the QTc. |
doi_str_mv | 10.1016/j.genhosppsych.2023.01.005 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2771334753</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163834323000051</els_id><sourcerecordid>2771334753</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-9d6ae56b1ffd9acb08730b7feb195e802349e240c1fe7f06be86a0da1085b0823</originalsourceid><addsrcrecordid>eNqNkUtLJDEUhYM4aPv4CxJcuamapFKvdie-QRgGdB1SyY2VprpSJmml3c0_n9u2yixnFUK-c07uuYSccpZzxuufi_wZxt7HaYpr3ecFK0TOeM5YtUNmvG1E1jS83CUzhEXWilLsk4MYFwyJohJ7ZF_UDa_rqpyRP9fWgk7UW6rG5D4cfXKariLQbk0nlRyMKdI3l3oade_e_dQHGJ2ifqQGNAwQEMKLVpPSLq3RyVCHmgDD9iV5mnqg2oeAYWDo70fqxgThVQ1H5IdVQ4Tjz_OQPN1cP17eZQ-_bu8vLx4yLVqWsrmpFVR1x601c6U7hnOyrrHQ8XkFLXZQzqEomeYWGsvqDtpaMaM4ayuEC3FIzra-U_AvK4hJLl3E3w9qBL-KssDShCibSiB6vkV18DEGsHIKbqnCWnImNyuQC_nvCuRmBZJxiQWj-OQzZ9UtwXxLvzpH4GoLAE776iDIqLFjDcZt2pHGu__J-Qtf1KIm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2771334753</pqid></control><display><type>article</type><title>Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Okayasu, Hiroaki ; Shinozaki, Takahiro ; Takano, Yumiko ; Sugawara, Norio ; Fujii, Kumiko ; Yasui-Furukori, Norio ; Ozeki, Yuji ; Shimoda, Kazutaka</creator><creatorcontrib>Okayasu, Hiroaki ; Shinozaki, Takahiro ; Takano, Yumiko ; Sugawara, Norio ; Fujii, Kumiko ; Yasui-Furukori, Norio ; Ozeki, Yuji ; Shimoda, Kazutaka</creatorcontrib><description>Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining the association between DC and the corrected QT interval (QTc) in schizophrenia patients.
We measured the DC and QTc of 138 schizophrenia patients. We then compared the DC of 86 age- and sex-matched healthy controls with that of 86 schizophrenia patients. We investigated the correlation of DC of approximately 138 schizophrenia patients with prescribed doses of antipsychotics using linear regression analysis. We compared the DC of schizophrenia patients with and without prolonged QT intervals.
We found DC significantly differed between schizophrenia patients on antipsychotic medication and healthy controls. Additionally, DC was negatively correlated with antipsychotic use, especially chlorpromazine, zotepine, olanzapine and clozapine, in a dose-dependent manner. There was no significant association between DC and the QTc.
Assessing DC could facilitate monitoring and identification of increased risk of cardiac mortality in patients with schizophrenia that take antipsychotics. Assessing both DC and the QTc may enhance the accuracy of predicting sudden cardiac death.
•The association of DC with antipsychotic use was examined in 138 persons with schizophrenia.•DC was significantly lower in schizophrenia using medication than in normal controls.•Antipsychotic use had a negative dose-dependent relationship with DC.•Using of chlorpromazine, zotepine, olanzapine, and clozapine was correlated with DC.•No association was observed between DC and the QTc.</description><identifier>ISSN: 0163-8343</identifier><identifier>EISSN: 1873-7714</identifier><identifier>DOI: 10.1016/j.genhosppsych.2023.01.005</identifier><identifier>PMID: 36716654</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antipsychotic Agents - adverse effects ; Antipsychotics ; Death, Sudden, Cardiac - etiology ; Deceleration ; Deceleration capacity ; Heart rate variability ; Humans ; Long QT Syndrome - chemically induced ; Long QT Syndrome - complications ; QT interval ; Schizophrenia ; Schizophrenia - complications ; Schizophrenia - drug therapy ; Sudden cardiac death</subject><ispartof>General hospital psychiatry, 2023-03, Vol.81, p.15-21</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-9d6ae56b1ffd9acb08730b7feb195e802349e240c1fe7f06be86a0da1085b0823</citedby><cites>FETCH-LOGICAL-c380t-9d6ae56b1ffd9acb08730b7feb195e802349e240c1fe7f06be86a0da1085b0823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0163834323000051$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36716654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okayasu, Hiroaki</creatorcontrib><creatorcontrib>Shinozaki, Takahiro</creatorcontrib><creatorcontrib>Takano, Yumiko</creatorcontrib><creatorcontrib>Sugawara, Norio</creatorcontrib><creatorcontrib>Fujii, Kumiko</creatorcontrib><creatorcontrib>Yasui-Furukori, Norio</creatorcontrib><creatorcontrib>Ozeki, Yuji</creatorcontrib><creatorcontrib>Shimoda, Kazutaka</creatorcontrib><title>Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval</title><title>General hospital psychiatry</title><addtitle>Gen Hosp Psychiatry</addtitle><description>Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining the association between DC and the corrected QT interval (QTc) in schizophrenia patients.
We measured the DC and QTc of 138 schizophrenia patients. We then compared the DC of 86 age- and sex-matched healthy controls with that of 86 schizophrenia patients. We investigated the correlation of DC of approximately 138 schizophrenia patients with prescribed doses of antipsychotics using linear regression analysis. We compared the DC of schizophrenia patients with and without prolonged QT intervals.
We found DC significantly differed between schizophrenia patients on antipsychotic medication and healthy controls. Additionally, DC was negatively correlated with antipsychotic use, especially chlorpromazine, zotepine, olanzapine and clozapine, in a dose-dependent manner. There was no significant association between DC and the QTc.
Assessing DC could facilitate monitoring and identification of increased risk of cardiac mortality in patients with schizophrenia that take antipsychotics. Assessing both DC and the QTc may enhance the accuracy of predicting sudden cardiac death.
•The association of DC with antipsychotic use was examined in 138 persons with schizophrenia.•DC was significantly lower in schizophrenia using medication than in normal controls.•Antipsychotic use had a negative dose-dependent relationship with DC.•Using of chlorpromazine, zotepine, olanzapine, and clozapine was correlated with DC.•No association was observed between DC and the QTc.</description><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotics</subject><subject>Death, Sudden, Cardiac - etiology</subject><subject>Deceleration</subject><subject>Deceleration capacity</subject><subject>Heart rate variability</subject><subject>Humans</subject><subject>Long QT Syndrome - chemically induced</subject><subject>Long QT Syndrome - complications</subject><subject>QT interval</subject><subject>Schizophrenia</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - drug therapy</subject><subject>Sudden cardiac death</subject><issn>0163-8343</issn><issn>1873-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtLJDEUhYM4aPv4CxJcuamapFKvdie-QRgGdB1SyY2VprpSJmml3c0_n9u2yixnFUK-c07uuYSccpZzxuufi_wZxt7HaYpr3ecFK0TOeM5YtUNmvG1E1jS83CUzhEXWilLsk4MYFwyJohJ7ZF_UDa_rqpyRP9fWgk7UW6rG5D4cfXKariLQbk0nlRyMKdI3l3oade_e_dQHGJ2ifqQGNAwQEMKLVpPSLq3RyVCHmgDD9iV5mnqg2oeAYWDo70fqxgThVQ1H5IdVQ4Tjz_OQPN1cP17eZQ-_bu8vLx4yLVqWsrmpFVR1x601c6U7hnOyrrHQ8XkFLXZQzqEomeYWGsvqDtpaMaM4ayuEC3FIzra-U_AvK4hJLl3E3w9qBL-KssDShCibSiB6vkV18DEGsHIKbqnCWnImNyuQC_nvCuRmBZJxiQWj-OQzZ9UtwXxLvzpH4GoLAE776iDIqLFjDcZt2pHGu__J-Qtf1KIm</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Okayasu, Hiroaki</creator><creator>Shinozaki, Takahiro</creator><creator>Takano, Yumiko</creator><creator>Sugawara, Norio</creator><creator>Fujii, Kumiko</creator><creator>Yasui-Furukori, Norio</creator><creator>Ozeki, Yuji</creator><creator>Shimoda, Kazutaka</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202303</creationdate><title>Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval</title><author>Okayasu, Hiroaki ; Shinozaki, Takahiro ; Takano, Yumiko ; Sugawara, Norio ; Fujii, Kumiko ; Yasui-Furukori, Norio ; Ozeki, Yuji ; Shimoda, Kazutaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-9d6ae56b1ffd9acb08730b7feb195e802349e240c1fe7f06be86a0da1085b0823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotics</topic><topic>Death, Sudden, Cardiac - etiology</topic><topic>Deceleration</topic><topic>Deceleration capacity</topic><topic>Heart rate variability</topic><topic>Humans</topic><topic>Long QT Syndrome - chemically induced</topic><topic>Long QT Syndrome - complications</topic><topic>QT interval</topic><topic>Schizophrenia</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - drug therapy</topic><topic>Sudden cardiac death</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okayasu, Hiroaki</creatorcontrib><creatorcontrib>Shinozaki, Takahiro</creatorcontrib><creatorcontrib>Takano, Yumiko</creatorcontrib><creatorcontrib>Sugawara, Norio</creatorcontrib><creatorcontrib>Fujii, Kumiko</creatorcontrib><creatorcontrib>Yasui-Furukori, Norio</creatorcontrib><creatorcontrib>Ozeki, Yuji</creatorcontrib><creatorcontrib>Shimoda, Kazutaka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>General hospital psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okayasu, Hiroaki</au><au>Shinozaki, Takahiro</au><au>Takano, Yumiko</au><au>Sugawara, Norio</au><au>Fujii, Kumiko</au><au>Yasui-Furukori, Norio</au><au>Ozeki, Yuji</au><au>Shimoda, Kazutaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval</atitle><jtitle>General hospital psychiatry</jtitle><addtitle>Gen Hosp Psychiatry</addtitle><date>2023-03</date><risdate>2023</risdate><volume>81</volume><spage>15</spage><epage>21</epage><pages>15-21</pages><issn>0163-8343</issn><eissn>1873-7714</eissn><abstract>Schizophrenia patients treated with antipsychotics are at higher risk of sudden cardiac death. Decreased deceleration capacity (DC) of the heart rate is an accurate predictor of cardiac mortality. We evaluated the risk of sudden cardiac death due to antipsychotic use by assessing DC and examining the association between DC and the corrected QT interval (QTc) in schizophrenia patients.
We measured the DC and QTc of 138 schizophrenia patients. We then compared the DC of 86 age- and sex-matched healthy controls with that of 86 schizophrenia patients. We investigated the correlation of DC of approximately 138 schizophrenia patients with prescribed doses of antipsychotics using linear regression analysis. We compared the DC of schizophrenia patients with and without prolonged QT intervals.
We found DC significantly differed between schizophrenia patients on antipsychotic medication and healthy controls. Additionally, DC was negatively correlated with antipsychotic use, especially chlorpromazine, zotepine, olanzapine and clozapine, in a dose-dependent manner. There was no significant association between DC and the QTc.
Assessing DC could facilitate monitoring and identification of increased risk of cardiac mortality in patients with schizophrenia that take antipsychotics. Assessing both DC and the QTc may enhance the accuracy of predicting sudden cardiac death.
•The association of DC with antipsychotic use was examined in 138 persons with schizophrenia.•DC was significantly lower in schizophrenia using medication than in normal controls.•Antipsychotic use had a negative dose-dependent relationship with DC.•Using of chlorpromazine, zotepine, olanzapine, and clozapine was correlated with DC.•No association was observed between DC and the QTc.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36716654</pmid><doi>10.1016/j.genhosppsych.2023.01.005</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-8343 |
ispartof | General hospital psychiatry, 2023-03, Vol.81, p.15-21 |
issn | 0163-8343 1873-7714 |
language | eng |
recordid | cdi_proquest_miscellaneous_2771334753 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Antipsychotic Agents - adverse effects Antipsychotics Death, Sudden, Cardiac - etiology Deceleration Deceleration capacity Heart rate variability Humans Long QT Syndrome - chemically induced Long QT Syndrome - complications QT interval Schizophrenia Schizophrenia - complications Schizophrenia - drug therapy Sudden cardiac death |
title | Effect of antipsychotic use by patients with schizophrenia on deceleration capacity and its relation to the corrected QT interval |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T20%3A07%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20antipsychotic%20use%20by%20patients%20with%20schizophrenia%20on%20deceleration%20capacity%20and%20its%20relation%20to%20the%20corrected%20QT%20interval&rft.jtitle=General%20hospital%20psychiatry&rft.au=Okayasu,%20Hiroaki&rft.date=2023-03&rft.volume=81&rft.spage=15&rft.epage=21&rft.pages=15-21&rft.issn=0163-8343&rft.eissn=1873-7714&rft_id=info:doi/10.1016/j.genhosppsych.2023.01.005&rft_dat=%3Cproquest_cross%3E2771334753%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2771334753&rft_id=info:pmid/36716654&rft_els_id=S0163834323000051&rfr_iscdi=true |